ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

VRX Bausch Health Cos

23.40
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bausch Health Cos NYSE:VRX NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 23.40 0.00 01:00:00

Valeant Share Price Surges on Citigroup Recommendation

19/11/2015 10:10pm

Dow Jones News


Valeant Pharma (NYSE:VRX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Valeant Pharma Charts.

The price of shares in Valeant Pharmaceuticals International Inc. has surged, reversing momentum after a Citigroup Inc. research note made favorable comments about the drug company and recommended buying its debt.

Valeant shares closed trading on New York Stock Exchange on Thursday at $84.00, up 15.7%, on heavy volume of 25.3 million shares.

The move contrasts with a rough past month for Valeant, in which its share price declined more than 50%.

Thursday's action enables Valeant to recoup at least a small part of the heavy losses the stock has seen since falling from an August high of $262.52 a share. The company has faced a string of questions about its drug pricing, disclosure and business strategy, especially concerning its now-ending relationship with a specialty pharmacy that distributed its drugs and helped drive Valeant's revenue growth.

The Citigroup note initiated coverage on Valeant's debt with an "overweight" rating. While the bank said Valeant has faced challenges recently, "we think much of the bad news has been priced in," and the debt is "a compelling buying opportunity."

Citi said Valeant and other specialty pharmaceutical companies are "asset rich, high cash flow companies," and "we think it is important that investors not lose sight of the broader fundamental picture."

Valeant has about $30 billion of debt, around $4 billion of which comes due in 2018. Most of its roughly $19 billion in bonds have been trading in the range of 80 to 90 cents on the dollar, according to FactSet.

Valeant bonds due in 2025 traded at 82 cents on the dollar on Wednesday to yield 9%; On Thursday, they were up to 82.5 cents for a yield of 8.9%. Bond yields fall when prices rise.

The Citi note also made favorable comments about two other specialty pharmaceutical companies, Endo International PLC and Mallinkrodt PLC, initiating coverage of both companies' debt with "marketweight" ratings. Endo share price was up 0.7% Thursday afternoon. Mallinkrodt shares were up 4.3%.

Liz Hoffman contributed to this article

 

Access Investor Kit for "CitiGroup Inc"

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US1729674242

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


(END) Dow Jones Newswires

November 19, 2015 16:55 ET (21:55 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.

1 Year Valeant Pharma Chart

1 Year Valeant Pharma Chart

1 Month Valeant Pharma Chart

1 Month Valeant Pharma Chart

Your Recent History

Delayed Upgrade Clock